FLT3 and acute myeloid leukemia: Additionally, while FLT3-TKD mutations are uncommon at initial presentation, they can emerge after FLT3 TKI therapy and cause secondary resistance, which also supports the use of gilteritinib in R/R FLT3 AML as it targets both ITD and TKD.